QN 019a
Alternative Names: QN-019aLatest Information Update: 25 Jul 2023
At a glance
- Originator Qihan Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 18 Jul 2023 National Medical Products Administration (NMPA) approves IND application for QN 019a in B-Cell Lymphoma in China
- 04 Nov 2021 Phase-I clinical trials in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT05379647)
- 04 Nov 2021 Phase-I clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Monotherapy, Second-line therapy or greater) in China (Parenteral) (NCT05379647)